Cytokinetics, Incorporated (CYTK)

Nasdaq · Healthcare · Biotechnology
$56.11-4.13%As of 2026-11-12 · USD
Day low $55.67Day high $58.58
52-week low $53.5552-week high $88.31
Market cap
$7.79B
Sector
Healthcare

Market data and research context for informational purposes. Not investment advice.

Technical indicators

Indicators from the 2026-11-12 daily bar; Bollinger %B and the average rows compare the latest price with those values. Prices in USD.

IndicatorValueReading
RSI (14)38.5In the neutral range (30 to 70)
MACD (12, 26, 9)-2.29Below its signal line (-2.02); histogram -0.27
Bollinger %B (20, 2)16%Inside the bands (54.11 to 66.71)
SMA 2060.41Price is 7.1% below
SMA 5064.47Price is 13.0% below
SMA 20069.83Price is 19.6% below
ATR (20)4.76% of priceAverage true range per day
52-week position7%In the lower part of the 53.55 to 88.31 range

About Cytokinetics, Incorporated

Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM.

Insider filings, 90 daysNo purchases and 16 sales (about $11.9M).
Latest fiscal yearEnded 2025-12-31: revenue of $88.04M and an operating margin of -695.4%.

More in Biotechnology